期刊文献+
共找到589篇文章
< 1 2 30 >
每页显示 20 50 100
Construction of A Prediction Model for Atrial Fibrillation in Patients with Dilated Cardiomyopathy and Heart Failure
1
作者 Kaizheng Liu Chengjie Liu 《Journal of Clinical and Nursing Research》 2024年第1期228-232,共5页
Dilated cardiomyopathy(DCM)is a common myocardial disease characterized by enlargement of the heart cavity and decreased systolic function,often leading to heart failure(HF)and arrhythmia.The occurrence of atrial fibr... Dilated cardiomyopathy(DCM)is a common myocardial disease characterized by enlargement of the heart cavity and decreased systolic function,often leading to heart failure(HF)and arrhythmia.The occurrence of atrial fibrillation(AF)is closely related to the progression and prognosis of the disease.In recent years,with the advancement of medical imaging and biomarkers,models for predicting the occurrence of AF in DCM patients have gradually become a research hotspot.This article aims to review the current situation of AF in DCM patients and explore the importance and possible methods of constructing predictive models to provide reference for clinical prevention and treatment.We comprehensively analyzed the risk factors for AF in DCM patients from epidemiological data,pathophysiological mechanisms,clinical and laboratory indicators,electrocardiogram and imaging parameters,and biomarkers,and evaluated the effectiveness of existing predictive models.Through analysis of existing literature and research,this article proposes a predictive model that integrates multiple parameters to improve the accuracy of predicting AF in DCM patients and provide a scientific basis for personalized treatment. 展开更多
关键词 dilated cardiomyopathy heart failure Atrial fibrillation Prediction model
下载PDF
Bioinformatics Analysis of the Relationship between Dilated Cardiomyopathy and Chronic Heart Failure
2
作者 Lanqing Yu Haidong Zhou +8 位作者 Bailu Deng Jiaochang Wei Mei Zhang Chongyao Xu Guiyun Wei Junxiu Zhou Jun Huang Qi Lu Shaowu Ye 《Journal of Biosciences and Medicines》 2024年第8期333-346,共14页
Objective: To screen and analyze the differentially expressed genes between dilated cardiomyopathy (DCM) and chronic heart failure (CHF) based on bioinformatics methods. Methods: The Gene Expression Omnibus (GEO) data... Objective: To screen and analyze the differentially expressed genes between dilated cardiomyopathy (DCM) and chronic heart failure (CHF) based on bioinformatics methods. Methods: The Gene Expression Omnibus (GEO) database was used for data retrieval, and the chip data GSE3585 was downloaded, which was the original data of DCM and normal control group. At the same time, the chip data GSE76701 was downloaded, which was the original data of CHF and control group. Differentially expressed mRNAs (DEmRNAs) were screened by R language limma package, the data were standardized, and the common differentially expressed genes were screened. GO function and KEGG pathway enrichment analysis were performed on the common differentially expressed genes. String11.0 online tool was used for data analysis to obtain differentially expressed genes, and the results were imported into Cytoscape 3.9.1 software. The results were imported into Cytoscape 3.9.1 software, and the common expression gene module was obtained by MOCDE algorithm. Nine Hub genes were obtained by 10 algorithms such as MCC. Results: A total of 248 differentially expressed genes were screened. GO analysis showed that differentially expressed genes were mainly concentrated in 9 different physiological and pathological processes. KEGG analysis showed that the main signaling pathways involved in differentially expressed genes were 2, and 9 key differentially expressed genes were predicted: NPPB, NPPA, MYH6, FRZB, ASPN, SFRP4, RPS4Y1, DDX3Y. Conclusion: This study preliminarily explored the molecular mechanism of DCM and CHF, and obtained the common differentially expressed genes of the two diseases. Further experimental studies are needed to verify the correlation between gene expression and clinicopathological features. Provide new ideas for clinical drug treatment research. 展开更多
关键词 dilated cardiomyopathy Chronic heart failure Bioinformatics Analysis Differentially Expressed Genes
下载PDF
Pediatric acute heart failure caused by endocardial fibroelastosis mimicking dilated cardiomyopathy:A case report
3
作者 Yao-Ying Xie Qiu-Li Li +1 位作者 Xin-Le Li Fan Yang 《World Journal of Clinical Cases》 SCIE 2023年第8期1771-1781,共11页
BACKGROUND Endocardial fibroelastosis(EFE)is a diffuse endocardial collagen and elastin hyperplasia disease of unknown etiology,which may be accompanied by myocardial degenerative changes leading to acute or chronic h... BACKGROUND Endocardial fibroelastosis(EFE)is a diffuse endocardial collagen and elastin hyperplasia disease of unknown etiology,which may be accompanied by myocardial degenerative changes leading to acute or chronic heart failure.However,acute heart failure(AHF)without obvious associated triggers is rare.Prior to the report of endomyocardial biopsy,the diagnosis and treatment of EFE are highly susceptible to being confounded with other primary cardiomyopathies.Here,we report a case of pediatric AHF caused by EFE mimicking dilated cardiomyopathy(DCM),with the aim of providing a valuable reference for clinicians to early identify and diagnose EFE-induced AHF.CASE SUMMARY A 13-mo-old female child was admitted to hospital with retching.Chest X-ray demonstrated enhanced texture in both lungs and an enlarged heart shadow.Color doppler echocardiography showed an enlarged left heart with ventricular wall hypokinesis and decreased left heart function.Abdominal color ultrasonography revealed a markedly enlarged liver.Pending the result of the endomyocardial biopsy report,the child was treated with a variety of resuscitative measures including nasal cannula for oxygen,intramuscular sedation with chlorpromazine and promethazine,cedilanid for cardiac contractility enhancement,and diuretic treatment with furosemide.Subsequently,the child’s endomyocardial biopsy report result was confirmed as EFE.After the above early interventions,the child’s condition gradually stabilized and improved.One week later,the child was discharged.During a 9-mo follow-up period,the child took intermittent low-dose oral digoxin with no signs of recurrence or exacerbation of the heart failure.CONCLUSION Our report suggests that EFE-induced pediatric AHF may present in children over 1 year of age without any apparent precipitants,and that the associated clinical presentations are grossly similar to that of pediatric DCM.Nonetheless,it is still possible to be diagnosed effectively on the basis of the comprehensive analysis of auxiliary inspection findings before the result of the endomyocardial biopsy is reported. 展开更多
关键词 Endocardial fibroelastosis dilated cardiomyopathy PEDIATRIC Acute heart failure Early identification and diagnosis
下载PDF
D-dimer level and long-term outcome in patients with end-stage heart failure secondary to idiopathic dilated cardiomyopathy 被引量:10
4
作者 Bi HUANG Yuan-Jing LI +3 位作者 Jian SHEN Yuan YANG Gang LIU Su-Xin LUO 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2019年第8期621-629,共9页
Background Previous studies had demonstrated hemostatic abnormalities in patients with heart failure (HF) and several studies have shown that abnormal coagulation indices, represented by elevated D-dimer, had prognost... Background Previous studies had demonstrated hemostatic abnormalities in patients with heart failure (HF) and several studies have shown that abnormal coagulation indices, represented by elevated D-dimer, had prognostic significance in patients with compatible or acute decompensated HF. However, the impact of D-dimer on the outcome in patients with end-stage HF remains unclear. Methods A total of 244 consecutive patients with end-stage HF due to idiopathic dilated cardiomyopathy (DCM) were prospectively enrolled from February 2011 to September 2014. D-dimer levels were measured and its prognostic value was assessed. Primary endpoint was all-cause mortality during the follow-up period. Secondary endpoints were stroke, bleeding, occurrence of sustained ventricular tachycardia or ventricular fibrillation, and major adverse cardiovascular events (MACE). Results D-dimer was significantly elevated in the non-survivors (median: 0.8 vs. 1.1 mg/L, P < 0.001). Traditional markers including B-type natriuretic peptide, troponin I, left ventricular ejection fraction, and left ventricular end-diastolic dimension provided limited prognostic value;but the addition of D-dimer refined the risk stratification. The optimal cut-off value of D-dimer to predict all-cause mortality was 0.84 mg/L by receiver operator characteristic analysis. Elevated D-dimer level was independently associated with increased risk of long-term all-cause mortality (HR = 2.315, 95% CI: 1.570–3.414, P < 0.001) and MACE (HR = 1.256, 95% CI: 1.058–1.490, P = 0.009), and the predictive value was independent of age, sex, atrial fibrillation and anticoagulation status. Conclusions Elevated D-dimer level was independently associated with poor long-term outcome in patients with end-stage HF secondary to idiopathic DCM, and the predictive value was superior to that of traditional prognostic markers. 展开更多
关键词 D-DIMER END-STAGE heart failure IDIOPATHIC dilated cardiomyopathy Long-term OUTCOME
下载PDF
Nemaline myopathy with dilated cardiomyopathy and severe heart failure: A case report 被引量:2
5
作者 Qian Wang Fan Hu 《World Journal of Clinical Cases》 SCIE 2021年第11期2569-2575,共7页
BACKGROUND Nemaline myopathy(NM)is a rare type of congenital myopathy,with an incidence of 1:50000.Patients with NM often exhibit hypomyotonia and varying degrees of muscle weakness.Skeletal muscles are always affecte... BACKGROUND Nemaline myopathy(NM)is a rare type of congenital myopathy,with an incidence of 1:50000.Patients with NM often exhibit hypomyotonia and varying degrees of muscle weakness.Skeletal muscles are always affected by this disease,while myocardial involvement is uncommon.However,with improvements in genetic testing technology,it has been found that NM with a mutation in the myopalladin(MYPN)gene not only causes slow,progressive muscle weakness but also results in dilated or hypertrophic cardiomyopathy.CASE SUMMARY A 3-year-old pre-school boy was admitted to our hospital with cough,edema,tachypnea,and an increased heart rate.The patient was clinically diagnosed with severe dilated cardiomyopathy and heart failure,and subsequent gene examination confirmed the diagnosis of NM with a mutation in MYPN.Captopril,diuretics,low-dose digoxin,and dobutamine were administered.After 22 d of hospitalization,the patient was discharged due to the improvement of clinical symptoms.During the follow-up period,the patient died of refractory heart failure.CONCLUSION Decreased muscular tone and dilated cardiomyopathy are common features of MYPN-mutated NM.Heart transplantation may be a solution to this type of cardiomyopathy. 展开更多
关键词 Nemaline myopathy Myopalladin dilated cardiomyopathy heart failure Whole-exome sequencing Case report
下载PDF
The combined efficacy of warming Yang therapy and Western of dilated cardiomyopathy with heart medicine the treatment failure:a meta-analysis
6
作者 Shan-Fu Chen Jian-Zhong Pang +1 位作者 You Zhai Ying-Qiang Zhao 《Drug Combination Therapy》 2020年第3期137-148,共12页
Background:To evaluate the clinical efficacy of oral administration of Chinese medicines with warming Yang effects and Western medicine in the treatment of heart failure caused by dilated cardiomyopathy.Methods:Seven ... Background:To evaluate the clinical efficacy of oral administration of Chinese medicines with warming Yang effects and Western medicine in the treatment of heart failure caused by dilated cardiomyopathy.Methods:Seven databases including Chinese National Knowledge Infrastructure,Weipu database,Wanfang database,China Biomedical Literature Service System,Cochrane library,PubMed,and Embase were searched.The search date was from established to October 2019.Randomized clinical trials of dilated cardiomyopathy patients with heart failure under the combination treatment of Chinese medicines with warming Yang effects and Western medicine were included.We then assessed the methodological quality of included literatures,extracted valid data and conducted systematically evaluation according to the Cochrane systematic review method.Outcome index included clinical efficacy,left ventricular ejection fraction,and brain natriuretic peptide.Results:Meta-analysis results showed that the clinical effective rate was higher in the combination group than that in the control group(RR=1.24,95%CI(1.14,1.34),P<0.01).In addition,the combination group could improve left ventricular ejection fraction compared with the control group(Std.MD=0.85,95%CI(0.69,1.01),P<0.01).However,the meta-analysis of brain natriuretic peptide levels showed that the included literatures have higher heterogeneity and the meta-analysis results were unstable.So the results of brain natriuretic peptide were abandoned.Conclusion:Oral administration of Chinese medicines with warming Yang effects combined with Western medicine is better than Western medicine alone in improving clinical effect and left ventricular ejection fraction,but it is not clear whether brain natriuretic peptide can be improved.Because the quality of the included studies is not high and inconsistent outcome index,more standardized and rigorous randomized double-blind controlled trials are needed to validate and guide clinical use. 展开更多
关键词 dilated cardiomyopathy heart failure Warming Yang META-ANALYSIS LVEF BNP
下载PDF
Contemporary characteristics and outcomes of adults with familial dilated cardiomyopathy listed for heart transplantation 被引量:1
7
作者 Mohamed Khayata Sadeer G Al-Kindi Guilherme H Oliveira 《World Journal of Cardiology》 CAS 2019年第1期38-46,共9页
BACKGROUND Familial dilated cardiomyopathy(FDCM) account for 20%-30% of non-ischemic cardiomyopathies(NICM). Previous published data showed that some patients with FDCM tend to have rapidly progressive disease; howeve... BACKGROUND Familial dilated cardiomyopathy(FDCM) account for 20%-30% of non-ischemic cardiomyopathies(NICM). Previous published data showed that some patients with FDCM tend to have rapidly progressive disease; however, five-year mortality was not significantly different in the familial and non-familial forms of NICM with optimal medical therapy.AIM To better define the characteristics and clinical outcomes of FDCM patients listed for heart transplantation(HT).METHODS We queried the United Network for Organ Sharing Registry to identify FDCM patients listed for HT between January 2008 and September 2015 and compared them to NICM and ischemic cardiomyopathy(ICM) patients. We included all patients ≥ 18 years old and we separated patients to three groups: FDCM, NICM and ICM. Chi-square test was used to compare between categorical variables, the t-test was used to compare between continues variables, and Cox-proportional hazards model was used to perform time-dependent survival analyses.RESULTS Of the 24809 adults listed for HT, we identified 677 patients(2.7%) with the diagnosis of FDCM. Compared to patients with NICM and ICM, FDCM patients were younger(FDCM 43.9 ± 13.5 vs NICM 50.9 ± 12.3, P < 0.001, vs ICM 58.5 ±8.1, P < 0.001), more frequently listed as status 2(FDCM 35.2% vs NICM 26.5%, P< 0.001), with significantly lower left ventricular assist device(LVAD) utilization(FDCM 18.4% vs NICM 25.1%, P < 0.001; vs ICM 25.6%, P < 0.001), but higher use of total artificial heart(FDCM 1.3% vs NICM 0.6%, P = 0.039; vs ICM 0.4%, P =0.002). Additionally, patients with FDCM were less frequently delisted for clinical deterioration or death and more likely to be transplanted compared to those with NICM [hazard ratio(HR): 0.617, 95% confidence interval(CI): 0.47-0.81; HR: 1.25,95%CI: 1.14-1.37, respectively], and ICM(HR: 0.5, 95%CI: 0.38-0.66; HR: 1.18,95%CI: 1.08-1.3, respectively). There was more frequent rejection among patients with FDCM(FDCM 11.4% vs NICM 9.8%, P = 0.28; vs ICM 8.4%, P = 0.034). One,three, and five post-transplant survival of patients with FDCM(91%, 88% and80%) was similar to those with NICM(91%, 84%, 79%, P = 0.225), but superior to those with ICM(89%, 82%, 75%, P = 0.008), respectively.CONCLUSION End-stage FDCM patients are more likely to be transplanted, more likely to have early rejection, and have similar or higher survival than patients with other cardiomyopathies. 展开更多
关键词 FAMILIAL dilated cardiomyopathy END-STAGE heart failure Wait list TRANSPLANT OUTCOMES
下载PDF
Differences in the predictive value of red cell distribution width for the mortality of patients with heart failure due to various heart diseases 被引量:10
8
作者 Yang ZHANG Yan WANG +4 位作者 Jin-Suo KANG Jin-Xing YU Shi-Jie YIN Xiang-Feng CONG Xi CHEN 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2015年第6期647-654,共8页
Background Increased red blood cell distribution width (RDW) is associated with adverse outcomes in patients with heart failure (HF). The objective of this study was to compare the differences in the predictive va... Background Increased red blood cell distribution width (RDW) is associated with adverse outcomes in patients with heart failure (HF). The objective of this study was to compare the differences in the predictive value of RDW in patients with HF due to different causes. Methods We retrospectively investigated 1,021 HF patients from October 2009 to December 2011 at Fuwai Hospital (Beijing, China). HF in these patients was caused by three diseases; coronary heart disease (CHD), dilated cardiomyopathy (DCM) and valvular heart disease (VHD). Patients were followed-up for 21 ~ 9 months. Results The RDW, mortality and survival duration were significantly different among the three groups. Kaplan-Meier analysis showed that the cumulative survival decreased significantly with increased RDW in patients with HF caused by CHD and DCM, but not in those with HF patients caused by VHD. In a multivariable model, RDW was identified as an independent predictor for the mortality of HF patients with CHD (P 〈 0.001, HR 1.315, 95% CI 1.122-1.543). The group with higher N-terminal pro-brain natriuretic peptide (NT-proBNP) and higher RDW than median had the lowest cumulative survival in patients with HF due to CHD, but not in patients with HF due to DCM. Conclusions RDW is a prognostic indicator for patients with HF caused by CHD and DCM; thus, RDW adds important information to NT-proBNP in CHD caused HF patients. 展开更多
关键词 Coronary heart disease dilated cardiomyopathy heart failure Red blood cell distribution width Valvular heart disease
下载PDF
Clinical characteristics, treatment and prognosis of patients with idiopathic dilated cardiomyopathy: a tertiary center experience 被引量:4
9
作者 Abdullah Hagar Xiao-Bo PU +2 位作者 Shi-Jian CHEN Jageshwar-Prasad Shah Mao CHEN 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2019年第4期320-328,共9页
Background Contemporary heart failure medications have led to considerable improvement in the survival of patients with heart failure. However,limited evidence is available regarding the effect of those medications in... Background Contemporary heart failure medications have led to considerable improvement in the survival of patients with heart failure. However,limited evidence is available regarding the effect of those medications in patients with idiopathic dilated cardiomyopathy (IDCM),particularly in China. We sought to analyze the trends in clinical characteristics and the prescription rate of recommended therapies and its prognostic impact in patients with IDCM. Methods From 2009 to 2016,1441 consecutive patients (age: 55±14 years,68% men,LVEF: 33%± 12%) fulfilling World Health Organization criteria for IDCM were enrolled in the current retrospective cohort study. Temporal trends of baseline clinical characteristics,treatment and prognosis were analyzed,and potential influential factors were explored. Results Rates of patients receiving angiotensin-converting enzyme inhibitors/angiotensin II receptors blockers,β-blockers,aldosterone receptor antagonists and diuretics increased from 55%,45%,58%,51% in 2009 to 67%,69%,71%,64% in 2016,respectively (P < 0.05);whereas,the proportion of patients receiving digoxin decreased from 39% in 2009 to 28% in 2016 (P < 0.05). The overall proportion of patients with optimal guideline-directed medical therapy (GDMT) was 44.6%;however,that rate increased from 33% in 2009 to 41%,49% and 56% in 2012,2014 and 2016 respectively (P < 0.05). Patients with optimal GDMT had a better outcome than those without,but there was no temporal trend toward improvement in the overall long-term prognosis of IDCM patients with the years. There was a trend towards admission of patients with milder disease and toward increased admission to a cardiology ward with the years. Conclusions An improvement in prescription rates of guideline-recommended medications in IDCM patients was observed. However,it remains suboptimal,and there is still some room for improvement. The prognosis of patients with optimal GDMT was better than those without. Moreover,the following patient category also had an improved prognosis: patients with LVEF ≥ 40%,with device therapy,and those admitted to a cardiology ward. 展开更多
关键词 dilated cardiomyopathy heart failure MEDICATIONS PROGNOSIS
下载PDF
A Heterozygous Phospholamban Variant(p.R14del)Leads to Left Ventricular Involvement and Heart Failure Phenotypes in Arrhythmogenic Right Ventricular Cardiomyopathy
10
作者 Han Mo Xiumeng Hua +4 位作者 Mengni Bao Zhe Sun Xiao Chen Mengda Xu Jiangping Song 《Phenomics》 2024年第1期13-23,共11页
This study aimed to determine the prevalence and clinical features of Arrhythmogenic Right Ventricular Cardiomyopathy(ARVC)caused by pathogenic mutations in the Phospholamban(PLN)gene.The study included 170 patients w... This study aimed to determine the prevalence and clinical features of Arrhythmogenic Right Ventricular Cardiomyopathy(ARVC)caused by pathogenic mutations in the Phospholamban(PLN)gene.The study included 170 patients who had a confrmed diagnosis of ARVC and underwent PLN genetic screening using next-generation sequencing.The fndings of this study provide valuable insights into the association between PLN mutations and ARVC,which can aid in the development of more efective diagnostic and treatment strategies for ARVC patients.Out of the patients evaluated,six had a rare pathogenic mutation in PLN with the same p.R14del variant.Family screening revealed that heterozygous carriers of p.R14del exhibited a defnite ARVC phenotype.In clinical studies,individuals with the p.R14del mutation experienced a similar rate of malignant arrhythmia events as those with classic desmosome mutations.After adjusting for covariates,individuals with PLN mutations had a two point one seven times greater likelihood of experiencing transplant-related risks compared to those who did not possess PLN mutations(95%CI 1.08–6.82,p=0.035).The accumulation of left ventricular fat and fbers is a pathological marker for ARVC patients with p.R14del mutations.In a cohort of 170 Chinese ARVC patients,three point fve percent of probands had the PLN pathogenic variant(p.R14del)and all were female.Our data shows that PLN-related ARVC patients are at high risk for ventricular arrhythmias and heart failure,which requires clinical diferentiation from classic ARVC.Furthermore,carrying the p.R14del mutation can be an independent prognostic risk factor in ARVC patients. 展开更多
关键词 Arrhythmogenic right ventricular cardiomyopathy PHOSPHOLAMBAN Left ventricular involvement heart failure Risk stratifcation
原文传递
Wilms tumor with dilated cardiomyopathy: A case report
11
作者 Saviga Sethasathien Chane Choed-Amphai +4 位作者 Kwannapas Saengsin Lalita Sathitsamitphong Pimlak Charoenkwan Kanokkan Tepmalai Suchaya Silvilairat 《World Journal of Clinical Oncology》 CAS 2019年第8期293-299,共7页
BACKGROUND Wilms tumor is the most common renal malignancy in childhood. It occurs primarily between the ages of 2 and 5 years. The usual manifestations are abdominal mass, hypertension, and hematuria. The case presen... BACKGROUND Wilms tumor is the most common renal malignancy in childhood. It occurs primarily between the ages of 2 and 5 years. The usual manifestations are abdominal mass, hypertension, and hematuria. The case presented here had an unusual presentation, with dilated cardiomyopathy and hypertension secondary to the Wilms tumor. CASE SUMMARY A 3-year-old boy presented with a 5-d history of irritability, poor appetite, and respiratory distress. His presenting clinical symptoms were dyspnea, tachycardia, hypertension, and a palpable abdominal mass at the left upper quadrant. His troponin T and pro-B-type natriuretic peptide levels were elevated. Echocardiography demonstrated a dilated hypokinetic left ventricle with an ejection fraction of 29%, and a suspected left renal mass. Computed tomography scan revealed a left renal mass and multiple lung nodules. The definitive diagnosis of Wilms tumor was confirmed histologically. The patient was administered neoadjuvant chemotherapy and underwent radical nephrectomy. After surgery, radiotherapy was administered, and the adjuvant chemotherapy was continued. The blood pressure and left ventricular function normalized after the treatments. CONCLUSION Abdominal mass, dilated cardiomyopathy and hypertension can indicate Wilms tumor in pediatric patients. Chemotherapy and tumor removal achieve successful treatment. 展开更多
关键词 dilated cardiomyopathy heart failure HYPERTENSION WILMS TUMOR Case report
下载PDF
心肌收缩力调节器治疗扩心病合并心力衰竭1例的围手术期护理体会
12
作者 吴晓鸿 李芳 +3 位作者 王圆圆 王韶屏 岳坤 柳景华 《中西医结合护理》 2024年第3期234-238,共5页
本文总结1例心肌收缩力调节器(CCM)治疗扩张型心肌病合并心力衰竭患者的围手术期护理经验。术前给予针对性评估,全面掌握患者生活自理、危险因素、心理情况,并制订针对性护理方案;术后加强病情观察、伤口护理和并发症预防;出院前给予健... 本文总结1例心肌收缩力调节器(CCM)治疗扩张型心肌病合并心力衰竭患者的围手术期护理经验。术前给予针对性评估,全面掌握患者生活自理、危险因素、心理情况,并制订针对性护理方案;术后加强病情观察、伤口护理和并发症预防;出院前给予健康宣教,指导康复运动,提升患者对CCM和疾病的自我管理能力,提高患者生活质量,积极预防疾病复发。 展开更多
关键词 心肌收缩力调节器 扩张型心肌病 心力衰竭 并发症 健康宣教 康复运动
下载PDF
中药黄芪的药理作用分析及临床应用效果
13
作者 董立 丛绍强 +2 位作者 程明丽 王丹 史家文 《中国卫生标准管理》 2024年第11期126-130,共5页
目的分析中药黄芪的药理作用及其临床应用效果。方法选取2022年10月—2023年10月青岛大学附属泰安市中心医院采用黄芪治疗的88例患者作为观察组,另选择同期应用西医治疗的88例作为对照组,观察运用中药黄芪后患者的临床疗效。结果观察组(... 目的分析中药黄芪的药理作用及其临床应用效果。方法选取2022年10月—2023年10月青岛大学附属泰安市中心医院采用黄芪治疗的88例患者作为观察组,另选择同期应用西医治疗的88例作为对照组,观察运用中药黄芪后患者的临床疗效。结果观察组(95.45%)急性心肌梗死合并心力衰竭总有效率高于对照组(72.73%)(P<0.05)。观察组(90.91%)扩张型心肌病伴心力衰竭总有效率高于对照组(68.18%)(P<0.05)。观察组糖尿病周围神经病变总有效率(100%)高于对照组(77.27%)(P<0.05)。观察组脑血栓总有效率(95.45%)高于对照组(68.18%)(P<0.05)。结论中药黄芪在治疗糖尿病周围神经病变、急性心肌梗死伴心衰、脑血栓后遗症以及扩张型心肌病合并心力衰竭患者中疗效较理想,为临床治疗提供有力依据,同时也为中药在心血管和神经系统疾病治疗中的应用提供新思路。但仍需要进一步的研究来验证其机制和安全性。 展开更多
关键词 中药黄芪 药理作用 糖尿病周围神经病变 急性心肌梗死 心力衰竭 脑血栓 扩张型心肌病
下载PDF
扩张型心肌病左心室辅助装置植入术后脑出血一例
14
作者 位艳伟 张云强 +2 位作者 田树光 韩丽 宋昱 《中国心血管杂志》 北大核心 2024年第1期14-16,共3页
1病例资料患者男性,66岁,因“间断胸闷气短10年,加重9 h”于2020年9月12日入院。患者入院前10年出现活动后胸闷气短,休息后可缓解,当地医院诊断“扩张型心肌病、心力衰竭”,于3年前行心脏再同步治疗除颤器(CRT-D)治疗。2020年1月7日开始... 1病例资料患者男性,66岁,因“间断胸闷气短10年,加重9 h”于2020年9月12日入院。患者入院前10年出现活动后胸闷气短,休息后可缓解,当地医院诊断“扩张型心肌病、心力衰竭”,于3年前行心脏再同步治疗除颤器(CRT-D)治疗。2020年1月7日开始,患者因活动后呼吸困难加重,活动耐量下降,伴乏力、纳差、恶心、下肢水肿,反复住院10余次。 展开更多
关键词 左心室辅助装置 扩张型心肌病 终末期心力衰竭 华法林 脑出血 血压管理
下载PDF
益气活血汤联合沙库巴曲缬沙坦治疗扩张型心肌病并心力衰竭的临床研究
15
作者 唐薇 常佩芬 +3 位作者 刘博 李天力 王静 王铭铭 《中西医结合心脑血管病杂志》 2024年第10期1756-1760,共5页
目的:观察益气活血汤联合沙库巴曲缬沙坦对扩张型心肌病(DCM)并心力衰竭病人临床症状及心室重构的影响。方法:选取2020年1月—2023年1月DCM并心力衰竭病人99例,按随机数字表法分为对照组49例(给予沙库巴曲缬沙坦治疗)和观察组50例(益气... 目的:观察益气活血汤联合沙库巴曲缬沙坦对扩张型心肌病(DCM)并心力衰竭病人临床症状及心室重构的影响。方法:选取2020年1月—2023年1月DCM并心力衰竭病人99例,按随机数字表法分为对照组49例(给予沙库巴曲缬沙坦治疗)和观察组50例(益气活血汤联合沙库巴曲缬沙坦治疗),比较两组临床疗效,治疗前后中医症状积分、心排量指标[心输出量(CO)、心指数(CI)、左室射血时间(LVET)、左心作功指数(LCWi)、外周阻力(SVR)]、心室重构指标[左室射血分数(LVEF)、左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)]、血清B型利钠肽原(NT-proBNP)、超敏C反应蛋白(hs-CRP)、心肌肌钙蛋白I(cTnI)水平。结果:观察组总有效率为88.00%,高于对照组的71.43%,差异有统计学意义(P<0.05)。治疗后,两组各项中医症状积分、SVR、LVESD、LVEDD、NT-proBNP、hs-CRP均低于治疗前(P<0.05),CO、CI、LVET、LCWi、LVEF均高于治疗前,且观察组优于对照组,差异均有统计学意义(P<0.05)。结论:益气活血汤联合沙库巴曲缬沙坦可改善DCM并心力衰竭病人临床症状、心功能及心室重构,安全性较高。 展开更多
关键词 扩张型心肌病 心力衰竭 益气活血汤 沙库巴曲缬沙坦 心室重构
下载PDF
右心室功能不全患者β-羟丁酸代谢特征及与临床指标的相关性分析
16
作者 考国营 徐刚 张颖 《检验医学与临床》 CAS 2024年第14期2094-2097,2101,共5页
目的 探讨右心室功能不全(RVD)患者β-羟丁酸(β-OHB)代谢特征及与临床指标的相关性。方法 选择2021年10月至2023年10月在该院心血管内科治疗的38例RVD患者纳入病例组。对照组按照年龄、性别、心血管危险因素等进行匹配,最终纳入47例研... 目的 探讨右心室功能不全(RVD)患者β-羟丁酸(β-OHB)代谢特征及与临床指标的相关性。方法 选择2021年10月至2023年10月在该院心血管内科治疗的38例RVD患者纳入病例组。对照组按照年龄、性别、心血管危险因素等进行匹配,最终纳入47例研究对象。根据RVD患者疾病类型将其分为致心律失常性右室心肌病(ARVC)组和肺动脉高压(PAH)组2个亚组。检测并对比所有研究对象的血浆N末端-B型脑钠肽前体(NT-proBNP)及β-OHB水平。采用Pearson相关分析RVD患者β-OHB水平与其他指标的相关性。结果 病例组、对照组在年龄、性别、体质量指数、吸烟,以及合并高血压、高脂血症、糖尿病患者比例等方面比较,差异均无统计学意义(P>0.05);与对照组比较,病例组血浆NT-proBNP和β-OHB水平明显升高(P<0.05)。ARVC组患者的血浆NT-proBNP[(2 126.1±708.9)pg/mL]和β-OHB[(142.4±55.9)μmol/L]水平高于PAH组患者[(688.4±317.7)pg/mL、(30.6±13.8)μmol/L],差异均有统计学意义(P<0.05)。Pearson相关分析显示,血浆β-OHB水平与NT-proBNP(r=0.734,P<0.001)和右心室舒张末期直径(r=0.445,P=0.005)呈正相关,与肺动脉压呈负相关(r=-0.423,P=0.008)。结论 RVD患者血浆β-OHB水平明显升高,尤其是ARVC患者高于单纯PAH患者,提示病理性的右室心肌病患者发生了显著的β-OHB水平改变。 展开更多
关键词 心力衰竭 Β-羟丁酸 右心功能不全 肺动脉高压 心律失常型心肌病
下载PDF
特发性扩张型心肌病患者miR-34a-5p、miR-17-5p表达水平及其与心衰的关系
17
作者 刘丹丹 孔洪 +1 位作者 邱清艳 樊毅虎 《分子诊断与治疗杂志》 2024年第7期1345-1349,共5页
目的 探讨特发性扩张型心肌病(IDCM)患者miR-34a-5p、miR-17-5p表达水平及其与心衰的关系。方法 选取2019年1月至2023年1月绵阳市游仙区中医医院和四川省人民医院联合收治的IDCM患者136例(IDCM组),根据IDCM患者是否继发心力衰竭分为心衰... 目的 探讨特发性扩张型心肌病(IDCM)患者miR-34a-5p、miR-17-5p表达水平及其与心衰的关系。方法 选取2019年1月至2023年1月绵阳市游仙区中医医院和四川省人民医院联合收治的IDCM患者136例(IDCM组),根据IDCM患者是否继发心力衰竭分为心衰组40例和非心衰组96例。选取同期68名无心脏病的健康志愿者设为对照组。比较IDCM组与对照组、心衰组与非心衰组的血清miR-34a-5p、miR-17-5p表达水平、N末端B型利钠肽(NT-proBNP)、超敏肌钙蛋白T(hs-TnT)、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)。分析血清miR-34a-5p、miR-17-5p表达水平与心功能指标的相关性。采用ROC曲线分析miR-34a-5p、miR-17-5p对IDCM继发心衰的预测价值。结果 IDCM组的血清miR-34a-5p、miR-17-5p表达水平高于对照组,差异有统计学意义(P<0.05)。IDCM组的血清NT-proBNP、hs-TnT水平高于对照组,LVEF低于对照组,LVEDD高于对照组,差异有统计学意义(P<0.05)。心衰组的血清miR-34a-5p、miR-17-5p表达水平高于非心衰组,差异有统计学意义(P<0.05)。心衰组的血清NT-proBNP水平高于非心衰组,LVEF低于非心衰组,LVEDD高于非心衰组,差异有统计学意义(P<0.05)。血清miR-34a-5p、miR-17-5p表达水平与血清NT-proBNP水平呈正相关(r=0.498,r=0.306,P<0.001)。血清miR-34a-5p联合miR-17-5p预测IDCM继发心衰的灵敏度为0.875,特异度为0.802。结论 IDCM患者存在miR-34a-5p、miR-17-5p表达水平上调情况,且miR-34a-5p、miR-17-5p表达水平与心衰具有关联,对预测心衰有一定价值。 展开更多
关键词 特发性扩张型心肌病 心力衰竭 miR-34a-5p miR-17-5p
下载PDF
血清补体C1q/肿瘤坏死因子相关蛋白3、波形蛋白水平与扩张型心肌病慢性心力衰竭患者预后的关系
18
作者 周松 郝清卿 +3 位作者 黄玲芳 达迎晓 崔振川 狄宁宁 《中国医药导报》 CAS 2024年第17期54-57,69,共5页
目的 探讨血清补体C1q/肿瘤坏死因子相关蛋白3(CTRP3)、波形蛋白(VTN)水平与扩张型心肌病慢性心力衰竭患者预后的关系。方法 选取2021年1月至2022年8月河北省邢台市中心医院收治的扩张型心肌病慢性心力衰竭患者179例,根据1年预后分为预... 目的 探讨血清补体C1q/肿瘤坏死因子相关蛋白3(CTRP3)、波形蛋白(VTN)水平与扩张型心肌病慢性心力衰竭患者预后的关系。方法 选取2021年1月至2022年8月河北省邢台市中心医院收治的扩张型心肌病慢性心力衰竭患者179例,根据1年预后分为预后不良组(63例)和预后良好组(116例)。采用酶联免疫吸附试验检测血清CTRP3、VTN水平。单因素和多因素logistic回归分析影响扩张型心肌病慢性心力衰竭患者预后的因素,受试者操作特征曲线分析血清CTRP3、VTN水平对扩张型心肌病慢性心力衰竭患者预后不良的预测价值。结果 随访1年,179例扩张型心肌病慢性心力衰竭患者预后不良发生率为35.20%(63/179)。两组年龄、慢性心力衰竭病程、心功能分级、左室射血分数(LVEF)、CTRP3、VTN比较,差异有统计学意义(P<0.05)。两组性别、吸烟史、饮酒史、合并疾病、收缩压、舒张压、治疗药物、器械辅助治疗比较,差异无统计学意义(P>0.05)。年龄增加[OR(95%CI):1.090(1.007~1.179)]、心功能分级增加[OR(95%CI):3.868(1.405~10.652)]、VTN升高[OR(95%CI):1.101(1.039~1.167)],LVEF增加[OR(95%CI):0.680(0.543~0.850)]和CTRP3升高[OR(95%CI):0.946(0.916~0.978)]为扩张型心肌病慢性心力衰竭患者预后不良的影响因素(P<0.05)。血清CTRP3联合VTN水平预测扩张型心肌病慢性心力衰竭患者预后不良的曲线下面积(0.878)大于血清CTRP3、VTN水平单独预测的0.782、0.787(Z=3.779、3.546,P<0.05)。结论 扩张型心肌病慢性心力衰竭患者血清CTRP3水平降低、VTN水平升高与预后不良密切相关,二者联合预测扩张型心肌病慢性心力衰竭患者预后不良的价值较高。 展开更多
关键词 扩张型心肌病 慢性心力衰竭 补体C1q/肿瘤坏死因子相关蛋白3 波形蛋白 预后
下载PDF
低剂量沙库巴曲缬沙坦钠联合酒石酸美托洛尔治疗扩张型心肌病心力衰竭的有效性
19
作者 文章 吴文 +3 位作者 李思柔 黄强 葛星峰 王剑 《中国医学创新》 CAS 2024年第29期141-144,共4页
目的:探讨低剂量沙库巴曲缬沙坦钠联合酒石酸美托洛尔治疗扩张型心肌病心力衰竭的有效性。方法:选取2021年1月—2023年1月新余钢铁集团有限公司中心医院收治的76例扩张型心肌病心力衰竭患者,随机分为对照组(n=36)、观察组(n=40)。对照... 目的:探讨低剂量沙库巴曲缬沙坦钠联合酒石酸美托洛尔治疗扩张型心肌病心力衰竭的有效性。方法:选取2021年1月—2023年1月新余钢铁集团有限公司中心医院收治的76例扩张型心肌病心力衰竭患者,随机分为对照组(n=36)、观察组(n=40)。对照组采用酒石酸美托洛尔治疗,观察组采用低剂量沙库巴曲缬沙坦钠联合酒石酸美托洛尔治疗。比较两组临床疗效、心功能指标、血清学指标及不良反应发生情况。结果:观察组治疗总有效率高于对照组(P<0.05)。治疗后,观察组左心室射血分数(LVEF)、每搏输出量(SV)水平均高于对照组,左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)及血清N-末端脑钠肽前体(NT-proBNP)、肌钙蛋白(cTnI)、肌酸激酶同工酶(CK-MB)水平均低于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:低剂量沙库巴曲缬沙坦钠联合酒石酸美托洛尔治疗扩张型心肌病心力衰竭临床效果确切,能有效改善患者心功能及血清学指标,且未增加不良反应发生率。 展开更多
关键词 扩张型心肌病 心力衰竭 低剂量沙库巴曲缬沙坦钠 酒石酸美托洛尔 心功能
下载PDF
左西孟旦联合沙库巴曲缬沙坦钠治疗扩张型心肌病并心力衰竭的临床疗效
20
作者 杨志超 王琦 +2 位作者 曹俊达 张文强 邹家旺 《临床合理用药杂志》 2024年第3期1-4,共4页
目的观察左西孟旦联合沙库巴曲缬沙坦钠治疗扩张型心肌病(DCM)并心力衰竭的临床疗效。方法回顾性选取2020年1月—2022年6月于九江市第一人民医院心血管内科住院的71例DCM并心力衰竭患者为研究对象,根据治疗方法分为A组23例、B组23例和C... 目的观察左西孟旦联合沙库巴曲缬沙坦钠治疗扩张型心肌病(DCM)并心力衰竭的临床疗效。方法回顾性选取2020年1月—2022年6月于九江市第一人民医院心血管内科住院的71例DCM并心力衰竭患者为研究对象,根据治疗方法分为A组23例、B组23例和C组25例。A组患者予以常规治疗,B组患者在A组基础上加用沙库巴曲缬沙坦钠片,C组患者在B组基础上联用左西孟旦注射液。3组疗程均为1个月。比较3组临床疗效,治疗前及治疗1个月后6 min步行距离、心功能指标(每搏输出量、左心室舒张末期内径、左心室射血分数)、N末端脑钠肽前体(NT-proBNP)水平。结果治疗1月后,A、B、C组治疗总有效率分别为60.87%、56.52%、92.00%,C组总有效率高于A、B组(χ2/P=6.572/0.010、8.042/0.005)。治疗1个月后,3组6 min步行距离均较治疗前延长,且C组长于A、B组,B组长于A组(P<0.05);3组每搏输出量、左心室射血分数高于治疗前,左心室舒张末期内径小于治疗前,且C组优于A、B组,B组优于A组(P<0.05);3组血清NT-proBNP水平低于治疗前,且C组低于A、B组,B组低于A组(P<0.05)。结论左西孟旦联合沙库巴曲缬沙坦钠治疗DCM并心力衰竭可增强疗效,明显降低血清NT-proBNP水平,减轻心肌损伤,极大程度地提高心功能,增强运动耐量。 展开更多
关键词 扩张型心肌病 心力衰竭 左西孟旦 沙库巴曲缬沙坦钠 治疗结果
下载PDF
上一页 1 2 30 下一页 到第
使用帮助 返回顶部